Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancerDaniel G. Stover, Nancy U. Lin, Carlos R. Gil Del Alcazar et al.|npj Breast Cancer|2018Cited by 150
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancerMaxwell R. Lloyd, Seth A. Wander, Komal Jhaveri et al.|Nature Reviews Clinical Oncology|2024Cited by 55
A Gene Panel Associated With Abemaciclib Utility in <i>ESR1</i>-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor ProgressionJamie O. Brett, Seth A. Wander, Leslie S.L. Kim et al.|JCO Precision Oncology|2023Cited by 16
Abstract PD2-03: Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclibJamie O. Brett, Seth A. Wander, Taronish D. Dubash et al.|Cancer Research|2022Cited by 1